CorMedix stock rises after Q1 earnings beat and raised guidance, driven by strong DefenCath demand and profitability growth.
Stock Earnings Results
May 14, 2026
Table of Contents
May 14, 2026
Shares of CorMedix (NASDAQ: CRMD) rose 10.17% after the company reported first-quarter results above expectations and raised its full-year 2026 revenue and adjusted EBITDA guidance. The move reflected investor confidence in strong DefenCath demand, revenue contribution from the Melinta portfolio, and improving profitability after adjusted EBITDA nearly tripled from the prior-year quarter.
CorMedix is a biopharmaceutical company focused on anti-infective products, including DefenCath for reducing catheter-related bloodstream infections in hemodialysis patients.
The company reported diluted EPS of $0.43, above estimates of $0.34, representing a 26.5% earnings surprise. Revenue came in at $127.43 million, above estimates of $109.85 million, with revenue growth of 226.1%.
CorMedix reported $127.4 million in net revenue for the quarter.
DefenCath contributed $97.5 million, supported by higher utilization from outpatient dialysis customers and the onboarding of a large dialysis organization in mid-2025. The company also benefited from a non-recurring $9.0 million favorable change in estimate tied to certain sales allowances.
The acquired Melinta portfolio contributed $29.9 million in revenue during the quarter.
That helped expand CorMedix beyond DefenCath alone and reflects the company’s larger combined product base following the acquisition.
CorMedix reported net income of $38.6 million, or $0.43 per diluted share.
Adjusted EBITDA reached $70.0 million, up from $23.6 million in the prior-year quarter. The increase shows stronger earnings leverage as DefenCath sales scaled and the acquired portfolio contributed for the full quarter.
CorMedix raised its full-year 2026 net revenue guidance to $325 million to $345 million.
The company also increased adjusted EBITDA guidance to $115 million to $135 million, giving investors a stronger full-year outlook after the Q1 beat.
CorMedix also highlighted positive Phase 3 topline results from the ReSPECT trial evaluating REZZAYO for prophylaxis of invasive fungal diseases in adult allogeneic stem cell transplant patients.
The company is preparing an FDA sNDA submission expected in the second half of 2026, with a potential expanded-indication commercial launch targeted for 2027.
Investors are likely to watch whether CorMedix can sustain DefenCath demand while expanding its anti-infective portfolio.
The key areas are:
CorMedix’s quarter was strong because the company paired a revenue beat with earnings leverage and higher guidance.
DefenCath remains the main driver, but the Melinta portfolio and REZZAYO pipeline opportunity give the company more than one growth lever. The key question is whether CorMedix can keep converting product demand into durable revenue and profitability through the rest of 2026.
Platforms like LevelFields track earnings beats, dividends, layoffs, clinical trial updates, and biotech stock reactions together, helping investors identify when healthcare companies are moving on both commercial execution and future pipeline catalysts.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE